Target Name: CDCA5
NCBI ID: G113130
Other Name(s): SORORIN | MGC16386 | Cell division cycle associated 5 | p35 | Sororin | cell division cycle associated 5 | cell division cycle-associated protein 5 | Cell division cycle-associated protein 5 | CDCA5_HUMAN

CDCA5 (Sororin) as a Drug Target and Biomarker: A Comprehensive Review

Abstract:

CDCA5 (Sororin) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is involved in various cellular processes, including cell adhesion, migration, and invasion. The aim of this review is to provide an overview of CDCA5 as a drug target and biomarker, highlighting its current status, potential therapeutic applications, and challenges in the pharmaceutical industry.

1. Introduction

CDCA5 (Sororin) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key player in various cellular processes, including cell adhesion, migration, and invasion. CDCA5 is expressed in various tissues and cells, including brain, pancreas, and cancer cells. The identification of CDCA5 as a potential drug target has significant implications for the development of new therapeutic strategies for various diseases, including cancer.

1. CDCA5 as a Drug Target

CDCA5 has been shown to be a potential drug target by various experiments. One of the most significant findings is the nuclear translocation of CDCA5 in response to various treatment conditions, such as cancer cells treated with chemotherapy or immunotherapy. The translocation of CDCA5 to the nuclear region suggests that it plays a role in the regulation of cellular processes that are relevant to cancer development and progression.

CDCA5 has also been shown to be involved in the regulation of cell adhesion and migration. Treatment with inhibitors of CDCA5, such as FAK inhibitors, has been shown to alter the migration and invasion of various cancer cell lines. These findings suggest that CDCA5 may be a promising target for cancer therapies that focus on enhancing the inhibition of cell migration and invasion.

1. CDCA5 as a Biomarker

CDCA5 has also been identified as a potential biomarker for various diseases, including cancer. The expression of CDCA5 has been shown to be associated with the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. Moreover, studies have shown that CDCA5 levels are significantly increased in the blood and various body tissues of individuals with cancer, providing a potential for its use as a diagnostic biomarker.

1. Challenges in the Pharmaceutical Industry

CDCA5 has also presented challenges in the pharmaceutical industry due to its complex structure and the lack of available resources for its purification and characterization. The high-throughput screening approach used to identify potential drug targets may not always lead to the validation of these targets. Additionally, the lack of information about the exact mechanism of action of CDCA5 makes it difficult to develop specific and effective therapies.

1. Conclusion

CDCA5 has been identified as a potential drug target and biomarker, with significant implications for the development of new therapeutic strategies for various diseases. The current understanding of CDCA5's role in cellular processes and its potential as a drug and biomarker highlights the need for further research to develop specific and effective therapies.

Protein Name: Cell Division Cycle Associated 5

Functions: Regulator of sister chromatid cohesion in mitosis stabilizing cohesin complex association with chromatin. May antagonize the action of WAPL which stimulates cohesin dissociation from chromatin. Cohesion ensures that chromosome partitioning is accurate in both meiotic and mitotic cells and plays an important role in DNA repair. Required for efficient DNA double-stranded break repair

More Common Targets

CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7